

**Mission Adult Oncology
Open to Enrollment Protocols**

Study #	Study Title
BREAST:	
NRG-BR003	A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
S1418	A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.
CCTG MA.39	A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer.
NSABP B-51	NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
NRG-BR004	Protocol Title: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
WF97116	A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment
S1706	A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
GENERAL:	
URCC16092	Phase II Study of Low-Dose Ibuprofen for Cognitive Impairment in Cancer Patients Receiving Chemotherapy
AMGEN 20170758	Amgen Neulasta Onpro: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia among Subjects with Non-myeloid Malignancies at High Risk for Febrile Neutropenia and receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of Febrile Neutropenia
DCP-001	Use of Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community oncology Research Program
EAY131 MATCH	Molecular Analysis for Therapy Choice (MATCH)
AFT-28 CANVAS	Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
GI	
EAQ162CD	Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent
GU	
I3Y-MC-JPCM	A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer
A031501	Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR) vs observation
S1802	Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

**Mission Adult Oncology
Open to Enrollment Protocols**

HEMATOLOGIC	
EA9161	A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
A041702	A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
NHLBI- MDS	Protocol for the collection of information and samples to be used in the study of MDS
A231602CD	Assessing Financial Difficulty in Patients with Blood Cancer
LUNG:	
LUNGMAP	A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Alliance A151216 (ALCHEMIST)	Adjuvant Lung CA Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
EA5142 Alchemist Sub-Study	Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers
A081105 Alchemist Sub-Study	Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Pts with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung CA
E4512 Alchemist Sub-Study	A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung CA : Crizotinib vs Placebo for Pts with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
EA5163	A Randomized, Phase III Study of First line Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post-progression in Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature driven Analysis. EA5163/S1709
NEURO- BRAIN:	
WF-1801	WF-1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy